RESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested Nvidia earnings and Trump's latest tariff threats.

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Nvidia is helping to prop up the U.S. stock market, and indexes are drifting higher. The S&P 500 rose 0.4% in early Thursday ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

Wall Street is pointing to gains before Thursday’s opening bell and ahead of government data being released this week on ...

U.S. health officials are reevaluating a $590M bird flu vaccine contract that was awarded to Moderna (NASDAQ:MRNA) by the ...